13F Holdings
中文EN

ANIP ANI PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1023024 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.9%
TTM net income YoY188.0%
TTM EPS YoY214.4%
Revenue 3-yr CAGR32.3%
Net income 3-yr CAGR105.9%

Margins

Gross margin61.1%
Operating margin16.0%
Net margin11.2%
FCF margin19.7%
EBITDA margin23.9%

Returns

ROE20.4%
ROA7.9%
ROIC (approx.)23.0%
Asset turnover0.70x

Leverage & solvency

Liabilities / assets59.4%
Debt / equity0.47x
Current ratio2.75x
Interest coverage5.44x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-7.6%
Payout ratio0.0%
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$883.37M$614.38M$486.82M$316.38M$216.14M
Cost of revenue$341.31M$250.21M$181.51M$138.78M$100.61M
Gross profit$542.06M$364.17M$305.30M$177.60M$115.53M
R&D expense$51.66M$44.58M$34.29M$22.32M$11.37M
SG&A expense$317.75M$249.64M$161.70M$124.04M$84.29M
Operating income$111.09M$584,000$46.97M-$35.28M-$39.79M
Interest expense$32.56M$33.63M$35.63M$28.51M$11.95M
Pretax income$95.79M-$22.21M$19.87M-$62.66M-$56.06M
Income tax$17.45M-$3.69M$1.09M-$14.77M-$13.46M
Net income$78.34M-$18.52M$18.78M-$47.90M-$42.60M
EBITDA$202.51M$68.31M$106.76M$21.69M$7.46M
EPS (basic)3.50-1.040.86-3.05-3.40
EPS (diluted)3.32-1.040.85-3.05-3.40
Weighted avg. shares (diluted)21.23M19.32M18.19M16.26M12.60M
Balance sheet
Cash & equivalents$285.58M$144.86M$221.12M$48.23M$100.30M
Receivables$281.08M$221.73M$162.08M$165.44M$128.53M
Inventory$143.07M$136.78M$111.20M$105.36M$81.69M
Current assets$753.12M$528.46M$519.82M$344.26M$321.77M
PP&E, net$62.48M$56.86M$44.59M$43.25M$52.67M
Goodwill$62.48M$59.99M$28.22M$28.22M$27.89M
Intangibles$479.53M$541.83M$209.01M$251.63M$294.12M
Total assets$1.44B$1.28B$904.42M$760.09M$771.60M
Current liabilities$278.11M$194.45M$145.48M$99.44M$87.54M
Short-term debt$17.27M$9.17M$850,000$850,000$850,000
Long-term debt$291.84M$309.11M$284.82M$285.67M$286.52M
Total debt$309.11M$318.28M$285.67M$286.52M$287.37M
Total liabilities$899.65M$855.94M$446.82M$421.55M$412.86M
Shareholders' equity$540.72M$403.68M$432.75M$313.69M$333.89M
Net debt$23.52M$173.42M$64.55M$238.29M$187.07M
Shares outstanding22.49M21.11M———
Cash flow statement
Operating cash flow$185.22M$64.02M$118.96M-$31.20M$3.32M
Capital expenditure$13.84M$16.24M$8.87M$8.88M$2.56M
Free cash flow$171.39M$47.78M$110.09M-$40.08M$765,000
Investing cash flow-$34.32M-$404.72M-$18.51M-$15.74M-$105.48M
Financing cash flow-$9.94M$264.94M$67.44M-$5.13M$194.59M
Depreciation & amortization$91.42M$67.73M$59.79M$56.97M$47.25M
Stock-based compensation$37.93M$29.34M$20.65M$14.60M$10.49M
Dividends paid$1.16M$1.62M$1.62M$1.62M$190,000
Share buybacks$12.21M$10.96M$4.99M$1.96M$890,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.